Jacques J. Koolen

Showing 1-14 of 14 articles

Invasive cardiovascular needs in South Africa: a view from afar up close

Holmes D, King S, Gershlick A, Marco J, Koolen J, Pichard A, Bassand J-P, Kettles D, Wijns W, Ntsekhe M

October 19, 2018 | 10.4244/EIJV14I8A153

Coronary interventions

Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016

Fajadet J, Haude M, Joner M, Koolen J, Lee M, Tölg R, Waksman R

September 18, 2016 | 10.4244/EIJV12I7A137

Coronary interventions

Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial

Haude M, Erbel R, Erne P, Verheye S, Degen H, Vermeersch P, Weissman N, Prati F, Bruining N, Waksman R, Koolen J

June 10, 2016 | 10.4244/EIJ-D-15-00371

Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data

Bourantas C, Serruys P, Nakatani S, Zhang Y-J, Farooq V, Diletti R, Ligthart J, Sheehy A, van Geuns R, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Rapoza R, Veldhof S, Onuma Y, Garcia-Garcia H

November 20, 2015 | 10.4244/EIJY14M10_06

Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Teeuwen K, Van den Branden B, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

March 20, 2015 | 10.4244/EIJY14M08_07

Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial

Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P

March 20, 2015 | 10.4244/EIJY14M04_11

Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J

March 20, 2014 | 10.4244/EIJV9I11A217

Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI

Brener S, Dambrink J-H, Maehara A, Chowdhary S, Gershlick A, Généreux P, Koolen J, Mehran R, Fahy M, Gibson M, Stone G

February 20, 2014 | 10.4244/EIJV9I10A201

Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Van den Branden B, Teeuwen K, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

November 29, 2013 | 10.4244/EIJV9I7A138

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Gogas B, Bourantas C, Garcia-Garcia H, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns R, De Bruyne B, Chevalier B, Thuesen L, Smits P, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston J, Serruys P

October 25, 2013 | 10.4244/EIJV9I6A115

Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial

Brugaletta S, Gomez-Lara J, Bruining N, Radu M, van Geuns R, Thuesen L, McClean D, Koolen J, Windecker S, Whitbourn R, Oberhauser J, Rapoza R, Ormiston J, Garcia-Garcia H, Serruys P

July 27, 2012 | 10.4244/EIJV8I3A54

Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study

Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston J, Windecker S, Whitbourn R, Dudek D, Dorange C, Veldhof S, Rapoza R, Regar E, Garcia-Garcia H, Serruys P

June 27, 2012

Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first

Gutiérrez-Chico J-L, van Geuns R, Koch K, Koolen J, Duckers H, Regar E, Serruys P

October 28, 2011 | 10.4244/EIJV7I6A114

European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club

Di Mario C, Werner G, Sianos G, Galassi A, Büttner J, Dudek D, Chevalier B, Lefèvre T, Schofer J, Koolen J, Sievert H, Reimers B, Fajadet J, Colombo A, Gershlick A, Serruys P, Reifart N

May 22, 2007

Latest news

EDITORIAL

A State-of-the Art and Mini Focus on Intracoronary OCT; Thrombectomy for Acute Ischaemic Stroke; and more…

June 11, 2021

NEW

Intracoronary OCT: State of the Art and Future Directions

Ziad A. Ali et al.

June 11, 2021

PCR Companion attending EuroPCR? Activate your free subscription!

May 28, 2021

TRIALS BOOK

Access the full Trials Book 2021

(Thanks to the support of Biotronik)

May 18, 2021

JAA

This Week's JAA's: ABSORB DAPT, OFR in predicting post-PCI FFR and more...

June 8, 2021

NEW

Joint EAPCI/ACVC expert consensus on pVADs

Alaide Chieffo et al.

May 31, 2021

JAA

New JAA's: Impact of HPR on clopidogrel monotherapy and more...